Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’
Authors:
Open Access
- 1 October 2021
- journal article
- letter
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 80 (10) , e162
Abstract
No abstract availableKeywords
Funding Information
- Mercator Stiftung (RIMUR)
- BMBF
- Immune Diagnostic Laboratory, Marien Hospital
This publication has 9 references indexed in Scilit:
- SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune responseAnnals of the Rheumatic Diseases, 2021
- Correspondence on ‘EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs’Annals of the Rheumatic Diseases, 2021
- COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort studyThe Lancet Rheumatology, 2021
- Adaptive immunity to SARS-CoV-2 and COVID-19Cell, 2021
- Robust T Cell Response Toward Spike, Membrane, and Nucleocapsid SARS-CoV-2 Proteins Is Not Associated with Recovery in Critical COVID-19 PatientsCell Reports Medicine, 2020
- SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19Nature, 2020
- 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseasesAnnals of the Rheumatic Diseases, 2020
- HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cellsBlood, 2006
- Rituximab treatment results in impaired secondary humoral immune responsivenessBlood, 2002